Pharmacogenetic-guided Choice of Post-surgery Analgesics

Plain-language summary

This study evaluates how pharmacogenetic testing (choosing medicines based on a person's genetic makeup) can guide the selection of pain relievers after surgery. It enrolled people assigned female at birth, aged 18 and older, who were scheduled for a hysterectomy or similar major gynecologic surgery. It was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University of Pennsylvania

Intervention

Pharmacogenetic testing, Pharmacist note with genotype-guided analgesic recommendations, Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines

Start date

10/13/2022

Estimated completion

2/1/2025

Countries

United States

Related genes

Locations

• Philadelphia, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Able and willing to provide informed consent
2. Assigned female at birth and aged 18 years or older at the time of study initiation
3. Major gynecologic surgery indicated and planned for hysterectomy, myomectomy, exploratory laparotomy, and open abdominal surgery
4. Willing to provide a buccal swab for PGx testing and comply with all study-related procedures

Exclusion Criteria:

1. Receiving chronic opioid therapy defined as ≥ 3 consecutive months of 1-month prescriptions for an opioid
2. Pregnancy
3. Breastfeeding
4. Treating physician does not want subject to participate